Oramed Pharmaceuticals, Inc. (ORMP) is up 11.21% Thursday In Premarket Trading

Oramed Pharmaceuticals, Inc. (ORMP) has gained Thursday morning, with the stock climbing 11.21% in pre-market trading to 3.57. ORMP's short-term technical score of 44 indicates that the stock has traded less bullishly over the last month than 56% of stocks on the market. In the Biotechnology industry, which ranks 109 out of 146 industries, Oramed Pharmaceuticals, Inc. ranks higher than 61% of stocks. Oramed Pharmaceuticals, Inc. has risen 45.25% over the past month, closing at $2.27 on January 25. During this period of time, the stock fell as low as $2.27 and as high as $3.29. ORMP has an average analyst recommendation of Sell. The company has an average price target of $4.25.

ORMP has an Overall Score of 54. Find out what this means to you and get the rest of the rankings on ORMP!

See Full ORMP Report

Oramed Pharmaceuticals, Inc. has a Long-Term Technical rank of 68. This means that trading over the last 200 trading days has placed the company in the upper half of stocks with 32% of the market scoring higher. In the Biotechnology industry which is number 70 by this metric, ORMP ranks better than 70% of stocks.

Important Dates for Investors in ORMP:

-Oramed Pharmaceuticals, Inc. is set to release earnings on 2024-03-04. Over the last 12 months, the company has reported EPS of $-0.41. -We do not have a set dividend date for Oramed Pharmaceuticals, Inc. at this time. Click Here To Get The Full Report on Oramed Pharmaceuticals, Inc. (ORMP)